Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ge healthcare as - mangafodipira trinātrija saturs - magnētiskās rezonanses attēlveidošanas - kontrasta multivide - Šīs zāles ir paredzētas tikai diagnostikas vajadzībām. kontrastvielas diagnostikas magnētiskās rezonanses attēlveidošanas (mri), lai atklātu bojājumus, aknu aizdomas, ka dēļ metastātiska slimība vai hepatocellular karcinomas. kā palīglīdzekli, lai mri, lai palīdzētu izmeklēšanā fokusa aizkuņģa dziedzera bojājumi.

Latvija - latviešu - Zāļu valsts aģentūra

biologische heilmittel heel gmbh, germany - causticum hahnemanni, rudens vēlziede (colchicum autumnale, citrullus colocynthis, dzelzs, metāla, litija benzoicum, pseudognaphalium obtusifolium, etiķkoku toxicodendron, filipendula ulmaria - Šķīdums injekcijām

Latvija - latviešu - Zāļu valsts aģentūra

biologische heilmittel heel gmbh, germany - sniedziņš cilvēki, tad, melilotus officinalis, lapseņu hornet, naja, platīna metāla, pallādiju, zeltu, iodatum, lilija lancifolium, ammonii bromatum, chamaelirium dzeltena, apis mellifica - pilieni iekšķīgai lietošanai, šķīdums

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - dzīvu kaķu panleucopenia vīruss / parvovīrusa + dzīvā kaķa saslimšanu vīrusu + dzīvā kaķa calicivirus + inaktivēta kaķu leikēmija vīruss - kaķi - lai aktīvi immunizētu kaķus no astoņu nedēļu vecuma pret: kaķu kalicivirozi, lai samazinātu klīniskās pazīmes. kaķu vīrusu rinotraheīta, lai samazinātu klīniskās pazīmes un vīrusu izdalīšanos. kaķu panleikopēnija, lai novērstu leikopēniju un samazinātu klīniskās pazīmes. kaķu leikēmija, lai novērstu pastāvīgu viremiju un ar to saistītās slimības klīniskās pazīmes. sākums imunitāti: 3 nedēļas pēc primārās vakcinācijas, lai panleucopenia un leikēmija sastāvdaļas, un 4 nedēļas pēc primārās vakcinācijas, lai calicivirus un saslimšanu vīrusu sastāvdaļas. imunitātes ilgums: vienu gadu pēc primārās vakcinācijas visām sastāvdaļām.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. imūnsistēmas sākums ir pierādīts vienu nedēļu pēc primārās vakcinācijas kursa rinotraheīta, kalicivīrusa, chlamydophila felis un panleikopēnijas sastāvdaļām. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vakcīnas - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.